WilmerHale Advises on Viridian Therapeutics’ $289 Million Public Offering

WilmerHale Advises on Viridian Therapeutics’ $289 Million Public Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in the public offering of 13,138,750 shares of common stock of Viridian Therapeutics, Inc. (Viridian) (Nasdaq: VRDN), reflecting the full exercise of the underwriters’ option to purchase additional shares. The Company received approximately $289 million in gross proceeds, excluding underwriting discounts, commissions, and other offering-related expenses. Viridian is a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases.

The WilmerHale team was led by Partner Lisa Firenze, with Counsel Liz Graffeo and Associates Rachael Joseph and Whitley Horning.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel